Stay updated on Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial
Sign up to get notified when there's something new on the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page.

Latest updates to the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page
- Check3 days agoChange DetectedA government funding notice was added at the top of the page. Related topics (Multiple Myeloma, MedlinePlus Genetics) were added, and the revision tag was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check10 days agoChange DetectedShow glossary was added and metadata labels updated to include Last Update Submitted that Met QC Criteria and Revision: v3.4.0. The term 'Multiple Myeloma' and several related topics (e.g., MedlinePlus Genetics) were removed from the related topics, reflecting a metadata adjustment rather than substantive study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check17 days agoChange Detected- Related topics updated: 'Multiple myeloma' is now listed and 'MedlinePlus Genetics' is added under related topics.SummaryDifference0.1%

- Check24 days agoChange DetectedThe top revision badge updated from v3.3.3 to v3.3.4, indicating a minor update.SummaryDifference0.0%

- Check38 days agoChange Detected- Removed related topics: 'Multiple myeloma' and 'MedlinePlus Genetics' from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedLocations section now lists New Jersey as the study site. HHS Vulnerability Disclosure link removed and page revision updated to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembro + Lenalid Post-ASCT in High-Risk MM Clinical Trial page.